![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EFCAB13 |
Gene summary for EFCAB13 |
![]() |
Gene information | Species | Human | Gene symbol | EFCAB13 | Gene ID | 124989 |
Gene name | EF-hand calcium binding domain 13 | |
Gene Alias | C17orf57 | |
Cytomap | 17q21.32 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q8IY85 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
124989 | EFCAB13 | male-WTA | Human | Thyroid | PTC | 1.25e-05 | 1.11e-01 | 0.1037 |
124989 | EFCAB13 | PTC01 | Human | Thyroid | PTC | 1.13e-11 | 2.33e-01 | 0.1899 |
124989 | EFCAB13 | PTC04 | Human | Thyroid | PTC | 1.54e-20 | 3.87e-01 | 0.1927 |
124989 | EFCAB13 | PTC05 | Human | Thyroid | PTC | 2.27e-12 | 4.74e-01 | 0.2065 |
124989 | EFCAB13 | PTC06 | Human | Thyroid | PTC | 5.53e-29 | 6.13e-01 | 0.2057 |
124989 | EFCAB13 | PTC07 | Human | Thyroid | PTC | 2.80e-17 | 2.94e-01 | 0.2044 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EFCAB13 | SNV | Missense_Mutation | novel | c.1285N>T | p.Pro429Ser | p.P429S | Q8IY85 | protein_coding | tolerated(0.32) | benign(0.042) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EFCAB13 | SNV | Missense_Mutation | novel | c.1633N>A | p.Asp545Asn | p.D545N | Q8IY85 | protein_coding | tolerated(0.25) | benign(0.223) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EFCAB13 | SNV | Missense_Mutation | novel | c.491N>A | p.Gly164Glu | p.G164E | Q8IY85 | protein_coding | tolerated(0.11) | benign(0.04) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EFCAB13 | SNV | Missense_Mutation | novel | c.1708N>A | p.Glu570Lys | p.E570K | Q8IY85 | protein_coding | tolerated(0.08) | benign(0.281) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EFCAB13 | SNV | Missense_Mutation | c.1958N>A | p.Val653Glu | p.V653E | Q8IY85 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EFCAB13 | SNV | Missense_Mutation | c.386N>A | p.Ser129Asn | p.S129N | Q8IY85 | protein_coding | tolerated(0.36) | benign(0.005) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EFCAB13 | SNV | Missense_Mutation | novel | c.1267N>G | p.Ser423Gly | p.S423G | Q8IY85 | protein_coding | deleterious(0) | benign(0.023) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EFCAB13 | SNV | Missense_Mutation | novel | c.296N>T | p.Arg99Ile | p.R99I | Q8IY85 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EFCAB13 | SNV | Missense_Mutation | c.2214N>T | p.Gln738His | p.Q738H | Q8IY85 | protein_coding | deleterious(0.01) | possibly_damaging(0.808) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EFCAB13 | SNV | Missense_Mutation | novel | c.489T>A | p.His163Gln | p.H163Q | Q8IY85 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |